Next Article in Journal
Fusogenic Viruses in Oncolytic Immunotherapy
Next Article in Special Issue
Geriatric Assessment in Older Patients with Acute Myeloid Leukemia
Previous Article in Journal
A Novel Acquired t(2;4)(q36.1;q24) with a Concurrent Submicroscopic del(4)(q23q24) in An Adult with Polycythemia Vera
Previous Article in Special Issue
Immunosenescence and Immunotherapy in Elderly Acute Myeloid Leukemia Patients: Time for a Biology-Driven Approach
Review

Role of Minimal (Measurable) Residual Disease Assessment in Older Patients with Acute Myeloid Leukemia

1
Hematology, Department of Biomedicine and Prevention, Tor Vergata University of Rome, 00133 Rome, Italy
2
Department of Medical and Molecular Genetics, King’s College, London SE1 9RT, UK
3
Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham B15 2TT, UK
*
Author to whom correspondence should be addressed.
Received: 2 May 2018 / Revised: 18 June 2018 / Accepted: 18 June 2018 / Published: 26 June 2018
(This article belongs to the Special Issue Treatment of Older Adults with Acute Myeloid Leukemia)
Minimal (or measurable) residual (MRD) disease provides a biomarker of response quality for which there is robust validation in the context of modern intensive treatment for younger patients with Acute Myeloid Leukemia (AML). Nevertheless, it remains a relatively unexplored area in older patients with AML. The lack of progress in this field can be attributed to two main reasons. First, physicians have a general reluctance to submitting older adults to intensive chemotherapy due to their frailty and to the unfavourable biological disease profile predicting a poor outcome following conventional chemotherapy. Second, with the increasing use of low-intensity therapies (i.e., hypomethylating agents) differing from conventional drugs in mechanism of action and dynamics of response, there has been concomitant skepticism that these schedules can produce deep hematological responses. Furthermore, age dependent differences in disease biology also contribute to uncertainty on the prognostic/predictive impact in older adults of certain genetic abnormalities including those validated for MRD monitoring in younger patients. This review examines the evidence for the role of MRD as a prognosticator in older AML, together with the possible pitfalls of MRD evaluation in older age. View Full-Text
Keywords: older AML; multiparametric flow-cytometry; RT-qPCR older AML; multiparametric flow-cytometry; RT-qPCR
Show Figures

Figure 1

MDPI and ACS Style

Buccisano, F.; Dillon, R.; Freeman, S.D.; Venditti, A. Role of Minimal (Measurable) Residual Disease Assessment in Older Patients with Acute Myeloid Leukemia. Cancers 2018, 10, 215. https://0-doi-org.brum.beds.ac.uk/10.3390/cancers10070215

AMA Style

Buccisano F, Dillon R, Freeman SD, Venditti A. Role of Minimal (Measurable) Residual Disease Assessment in Older Patients with Acute Myeloid Leukemia. Cancers. 2018; 10(7):215. https://0-doi-org.brum.beds.ac.uk/10.3390/cancers10070215

Chicago/Turabian Style

Buccisano, Francesco, Richard Dillon, Sylvie D. Freeman, and Adriano Venditti. 2018. "Role of Minimal (Measurable) Residual Disease Assessment in Older Patients with Acute Myeloid Leukemia" Cancers 10, no. 7: 215. https://0-doi-org.brum.beds.ac.uk/10.3390/cancers10070215

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop